Baihua Pharmaceutical announced that the company's stock rose and stopped for six consecutive trading days from August 4 to August 11, 2026, with an increase of 77.07%. The company issued a stock trading risk warning notice. The company is a CRO enterprise that mainly develops small-molecule chemical generic drugs. It does not involve R&D of innovative drugs, and there have been no major changes in its main business. The first quarter of 2026 achieved operating income of 67.1829 million yuan, a year-on-year decrease of 30.68%; net profit attributable to shareholders of listed companies was 6.6427 million yuan, a year-on-year decrease of 67.94%. The company's latest rolling price-earnings ratio is 184.25 times, and the rolling price-earnings ratio for the same industry is 34.96 times.

Baihua Pharmaceutical announced that the company's stock rose and stopped for six consecutive trading days from August 4 to August 11, 2026, with an increase of 77.07%. The company issued a stock trading risk warning notice. The company is a CRO enterprise that mainly develops small-molecule chemical generic drugs. It does not involve R&D of innovative drugs, and there have been no major changes in its main business. The first quarter of 2026 achieved operating income of 67.1829 million yuan, a year-on-year decrease of 30.68%; net profit attributable to shareholders of listed companies was 6.6427 million yuan, a year-on-year decrease of 67.94%. The company's latest rolling price-earnings ratio is 184.25 times, and the rolling price-earnings ratio for the same industry is 34.96 times.